Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Resources
Biosimilars Excellence Forum
Blogs
Expert Insights
Latest News
Mantle Cell Lymphoma Excellence Forum
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ASCO Genitourinary Cancers Symposium
ASH Annual Meeting and Exposition
Oncology CME
About
About Us
Contact
Cost-Effectiveness Research
Featured
Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition with cisplatin-based chemotherapy for muscle-invasive…
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy…
News
Cost-Effectiveness of Selective Internal Radiotherapy vs Sorafenib in HCC
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
News
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Targeted BRCA or multiple gene screening is cost-effective for preventing breast and ovarian cancer, according to a…
News
Doublet Therapy Unlikely Cost-Effective for Metastatic BRAF Variant Colorectal Cancer
While the use of doublet therapy for treating patients with metastatic BRAF variant colorectal cancer is associated…
News
Cost-Effectiveness of Selective Internal Radiotherapy vs Sorafenib in HCC
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Doublet Therapy Unlikely Cost-Effective for Metastatic BRAF Variant Colorectal Cancer
RT Added to ADT Cost-Effective vs ADT Alone for Metastatic Prostate Cancer
Interviews
Discussing Biosimilars: Barriers and Cost-Effectiveness
Blog
PCORI to Incorporate Cost But Not Cost-Effectiveness in its New Principles
Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
Podcast
Is CAR-T Therapy Comparable to Past Innovative Therapies in Regard to Health Outcomes, Cost-Effectiveness?
Conference Coverage
Nivolumab Plus Ipilimumab Cost-Effective for Intermediate or Poor Risk RCC
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top